MoonLake Immunotherapeutics (MLTX) Non-Current Debt (2025 - 2026)
MoonLake Immunotherapeutics' (MLTX) quarterly Non-Current Debt came in at $99.0 million in Q1 2026, up 35.6% year-on-year from $73.0 million in Q1 2025, and up 33.63% quarter-over-quarter from $74.1 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Non-Current Debt (2025 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $99.0 million for Q1 2026.
- On a quarterly basis, Non-Current Debt rose 35.6% year-over-year to $99.0 million in Q1 2026; TTM through Mar 2026 was $99.0 million, a 35.6% increase from a year earlier, with the FY2025 full-year figure at $74.1 million, changed N/A from the prior year.
- Non-Current Debt advanced to $99.0 million in Q1 2026 per MLTX's latest filing, from $74.1 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $99.0 million in Q1 2026 and bottomed at $73.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | MoonLake Immunotherapeutics | 1.38 Bn | 1.02 Bn | - | 99.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.02 Mn |
| Dec 31, 2025 | 74.10 Mn |
| Sep 30, 2025 | 73.70 Mn |
| Jun 30, 2025 | 73.40 Mn |
| Mar 31, 2025 | 73.02 Mn |